CIK 0000818033
- Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 942875566
- Phone
- +1 858-251-4400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-12-21 | Johnson Craig A Director | Grant or award | +3,000 | 3,840 | ||
| 2020-12-21 | Johnson Craig A Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2020-12-21 | DAVIS STEPHEN Director | Grant or award | +3,000 | 3,000 | ||
| 2020-12-21 | DAVIS STEPHEN Director | Grant or award · Stock Option (Right to Buy) | +18,000 | 18,000 | ||
| 2020-10-30 | POYHONEN JOHN President & CCO | Other acquisition | +637 | $11.65 | $7K | 18,780 |
| 2020-10-13 | Peraza Lisa VP, Chief Accounting Officer | Grant or award · Employee Stock Option (Right to Buy) | +103,000 | 103,000 | ||
| 2020-10-13 | Peraza Lisa VP, Chief Accounting Officer | Grant or award · Restricted Stock Units | +8,833 | 8,833 | ||
| 2020-10-13 | MANHARD KIMBERLY EVP, Drug Development | Grant or award · Employee Stock Option (Right to Buy) | +120,000 | 120,000 | ||
| 2020-10-13 | MANHARD KIMBERLY EVP, Drug Development | Grant or award · Restricted Stock Units | +20,000 | 20,000 | ||
| 2020-10-13 | POYHONEN JOHN President & CCO | Grant or award · Employee Stock Option (Right to Buy) | +170,000 | 170,000 | ||
| 2020-10-13 | POYHONEN JOHN President & CCO | Grant or award · Restricted Stock Units | +20,000 | 20,000 | ||
| 2020-10-13 | Quart Barry D Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +350,000 | 350,000 | ||
| 2020-10-13 | Quart Barry D Chief Executive Officer | Grant or award · Restricted Stock Units | +58,333 | 58,333 | ||
| 2020-10-13 | Christian Waage Director | Grant or award · Stock Option (Right to Buy) | +437 | 437 | ||
| 2020-10-13 | DAVIS STEPHEN Director | Grant or award · Stock Option (Right to Buy) | +765 | 765 | ||
| 2020-05-01 | MANHARD KIMBERLY Executive VP, Drug Development | Sale | −1,158 | $13.97 | $16K | 0 |
| 2020-04-30 | Quart Barry D Chief Executive Officer | Other acquisition | +1,158 | $12.12 | $14K | 89,226 |
| 2020-04-30 | MANHARD KIMBERLY Executive VP, Drug Development | Other acquisition | +1,158 | $12.12 | $14K | 1,158 |
| 2020-04-15 | Christian Waage Director | Grant or award · Stock Option (Right to Buy) | +713 | 713 | ||
| 2020-04-15 | DAVIS STEPHEN Director | Grant or award · Stock Option (Right to Buy) | +1,426 | 1,426 |
Page 29 of 38 · 746 trades